Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Use of In Vitro Assays in Selection of Compatible Platelet Donors

Use of In Vitro Assays in Selection of Compatible Platelet Donors Although HLA‐matched platelet transfusions are of value in the support of some alloimmunized thrombocytopenic patients, poor posttransfusion increments can be observed following HLA‐matched platelet transfusions and conversely good posttransfusion increments may result after HLA‐mismatched platelet transfusions. We have explored the possibility that in vitro assays in addition to HLA typing might better select compatible donors for refractory recipients. Our studies suggested that a platelet migration inhibition assay is predictive of platelet transfusion responses in HLA‐compatible and incompatible donor‐recipient pairs, while lymphocyto‐toxicity is predictive of posttransfusion increments only in HLA‐incompatible donor‐recipient pairs. Granulocy‐totoxicity, microleukoagglutination, and capillary leu‐koagglutination showed no value in predicting platelet transfusion increments, either in HLA‐compatible or incompatible donor‐recipient pairs. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Transfusion Wiley

Use of In Vitro Assays in Selection of Compatible Platelet Donors

Loading next page...
 
/lp/wiley/use-of-in-vitro-assays-in-selection-of-compatible-platelet-donors-dUWQZ0Esrm

References (29)

Publisher
Wiley
Copyright
Copyright © 1980 Wiley Subscription Services
ISSN
0041-1132
eISSN
1537-2995
DOI
10.1046/j.1537-2995.1980.20180125040.x
Publisher site
See Article on Publisher Site

Abstract

Although HLA‐matched platelet transfusions are of value in the support of some alloimmunized thrombocytopenic patients, poor posttransfusion increments can be observed following HLA‐matched platelet transfusions and conversely good posttransfusion increments may result after HLA‐mismatched platelet transfusions. We have explored the possibility that in vitro assays in addition to HLA typing might better select compatible donors for refractory recipients. Our studies suggested that a platelet migration inhibition assay is predictive of platelet transfusion responses in HLA‐compatible and incompatible donor‐recipient pairs, while lymphocyto‐toxicity is predictive of posttransfusion increments only in HLA‐incompatible donor‐recipient pairs. Granulocy‐totoxicity, microleukoagglutination, and capillary leu‐koagglutination showed no value in predicting platelet transfusion increments, either in HLA‐compatible or incompatible donor‐recipient pairs.

Journal

TransfusionWiley

Published: Jan 2, 1980

There are no references for this article.